Published in Telemedicine Law Weekly, July 8th, 2006
Bionovo researchers hypothesize that estrogen receptor beta (ERBeta)-selective estrogens may be a safer alternative for women to treat menopausal symptoms, because they do not cause proliferation of breast cancer or uterine cells like estrogens used in current hormone replacement therapy (HRT) regimens.
Bionovo has isolated several key compounds from MF101 that show ERBeta-selectivity in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Telemedicine Law Weekly